Capecitabine/cyclophosphamide/methotrexate for patients with metastatic breast cancer: A dose-finding, feasibility, and efficacy study

Clinical Breast Cancer

Volumn 7, Issue 4, 2006, Pages 321-325

  Mariani, Gabriella ^a   Petrelli, Fausto ^a   Zambetti, Milvia ^a   Moliterni, Angela ^a   Fasolo, Angelica ^a   Marchianò, Alfonso ^a   Valagussa, Pinuccia ^a   Gianni, Luca ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anthracyclines; Antitumor activity; Combination chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEASIBILITY STUDY; FEMALE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; METASTASIS POTENTIAL; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33750885702     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.044     Document Type: Article

References (32)

1. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294:405-410.
2. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005; 330:217-222.
3. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 1:2651-2658.
4. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 1:602-611.
5. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-308.
6. Ng JS, Cameron DA, Leonard RC. Infusional 5-fluorouracil in breast cancer. Cancer Treat Rev 1994; 20:357-364.
7. Zambetti M, Mariani G, Demicheli R, et al. Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel. Breast Cancer Res Treat 2000; 62:135-139.
8. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27:23-44.
9. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropy-rimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
10. Ishikawa T, Utah M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55:1091-1097.
11. Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58:685-690.
12. Beek A, Etienne MC, Cheradame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30:1517-1522.
13. Nita ME, Tominaga O, Nagawa H, et al. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer. Hepatogastroenterology 1998; 45:2117-2122.
14. Ishikawa Y, Kubota T, Otani Y, et al. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000; 91:105-112.
15. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase, Clin Cancer Res 2000; 6:1322-1327.
16. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreted metastatic breast carcinoma patients. Cancer 2001; 92:1759-1768.
17. Reichardt P, von Minckwitz G, Thuss-Patience PC, et al. Multicenter, phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer, relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14:1227-1233.
18. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40:536-542.
19. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-493.
20. O'Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomised, open-label, phase II trial of oral capecitabine (Xeloda®) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12:1247-1254.
21. Talbot D, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86:1367-1372.
22. Batista N, Perez-Manga G, Constenla M, et al. Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer 2004; 90:1740-1746.
23. Blum JL, Dees EC, Chacko A, et al. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2006; 24:4384-4390.
24. Gradishar WJ, Meza LA, Amin B, et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 2004; 15:2321-2327.
25. Cancer therapy evaluation program, common terminology criteria for adverse events. Version 3.0. Available at: http://ctep.cancer.gov. Accessed: August 9, 2006.
26. De Vita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 6th Ed. Philadelphia, PA: Lippincott Wiliams and Wilkins, 2001.
27. Anderson N, Lokich J. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration and cost comparisons. Cancer 1992; 70:998-1002.
28. Seidman AD, O'Shaughnessy J, Misset JL. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002; 7:20-28.
29. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
30. Welt A, von Minckwitz G, Oberhoff C, et al. Phase I/Il study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 2005; 16:64-69.
31. Schott AF, Rae JM, Griffith KA, et al. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol 2005; 8:1-7.
32. Andres R, Mayordomo JI, Lara R, et al. Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 2005; 6:158-162.